Navigation Links
Tianyin Pharmaceutical, Co. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 11 at 10:50 am ET
Date:8/31/2009

CHENGDU, China, Aug. 31 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co. Inc. (NYSE Amex: TPI), a developer, manufacturer and supplier of modernized traditional Chinese medicine ("TCM") and generic pharmaceuticals in China, today announced that it will present at the Rodman & Renshaw Annual Global Investment Conference, to be held September 9-11, 2009, at the New York Palace Hotel in New York City.

Mr. Stewart Lor, Director, is scheduled to present at 10:50 am ET on Friday, September 11th, 2009 in the Kennedy I salon (4th Floor). Mr. Allen Tang, assistant to the CEO, will join Mr. Lor for one-on-one meetings with conference attendees throughout the three-day event. The presentation will discuss the Company's diversified product portfolio, customer base addressable market, competitive landscape, and recent financial results. Mr. Lor will provide additional details on the $126 billion government sponsored healthcare reform plan and its potential benefits to the Company's long-term growth strategy.

Registration is mandatory. For more information on the conference, contact your Rodman and Renshaw representative, or to register, please visit http://www.rodmanandrenshaw.com/ or email Lily Khaykina at lk@rodmanrenshaw.com. Please book all one-on-one requests directly through the meeting software interface provided by Rodman and Renshaw.

Additionally, Mr. Lor and Mr. Tang will host meetings throughout the New York area on September 11, 2009. To request a meeting please contact Mr. Matt Hayden of HC International at 760-613-3695-271 or by email at matt.hayden@hcinternational.net.

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 39 products, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 40 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 720 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 1,365 employees. For more information about Tianyin, please visit http://www.tianyinpharma.com .

Safe Harbor Statement

The Statements which are not historical facts during the presentation are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

    For more information, please contact:

    For the Company:
     Allen Tang, Ph.D., MBA, Assistant to the CEO in China
     Tel:   +86-158-2122-5642
     Email: Allen.y.tang@gmail.com

    Investors:
     Mr. Matthew Hayden, HC International
     Tel:   +1-561-245-5155
     Email: matt.hayden@hcinternational.net
     Web:  http://www.hcinternational.net

'/>"/>
SOURCE Tianyin Pharmaceutical Co. Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Sanqi Tablets and Yinqiao Jiedu Tablets
2. Tianyin Pharmaceutical Co., Inc. Announces Cash Dividend to Common Stockholders
3. Tianyin Pharmaceutical Co., Inc. Adopts New Sales Strategy for Azithromycin Dispersible Tablets
4. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Wednesday, February 18, 2009 at 8:45 a.m. EST
5. Tianyin Pharmaceutical Co., Inc. Implements New Sales and Marketing Strategy to Drive Revenue Growth
6. Tianyin Pharmaceutical Co., Inc. Announces First Quarter 2009 Financial Results
7. Tianyin Pharmaceutical Co., Inc. to Present at Rodman & Renshaw Annual Global Investment Conference in New York City on November 11, 2008 at 12:00 p.m. EST
8. Tianyin Pharmaceutical to Present at the Brean Murray All-Cap All-China Conference in New York City on May 20, 2008 at 10:15 a.m. EDT
9. Tianyin Pharmaceutical Announces SFDA Approval to Market Azithromycin Dispersible Tablets
10. Tianyin Pharmaceutical Appoints Three New Independent Board Members
11. Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... Massachusetts (PRWEB) , ... May 17, 2017 , ... ... company specializing in medical device compliance and commercialization, has just released version 9.0 ... of work into this latest version of Cockpit,” says David Cronin, CEO of ...
(Date:5/18/2017)... ... May 17, 2017 , ... G-CON Manufacturing, Inc., the ... Officer, Maik Jornitz, was recognized as a Top 10 Industry Influencer on The ... “involved in bettering the pharma industry and bringing life-changing medicines to market” across ...
(Date:5/16/2017)... ... May 16, 2017 , ... Genedata, a leading provider ... User Group Meetings, which will be held in Boston, Cambridge/UK, Shanghai, and ... in screening data analysis and learn about the latest advances in screening technologies ...
(Date:5/16/2017)... ... May 16, 2017 , ... Cynvenio Biosystems, Inc. ... ClearID Lung Cancer blood test. Leveraging a highly-sensitive next-generation sequencing panel of 11 ... to quickly and accurately identify tumor-related genetic mutations that can be treated with ...
Breaking Biology Technology:
(Date:3/27/2017)... N.Y. , March 27, 2017  Catholic ... Information and Management Systems Society (HIMSS) Analytics for ... EMR Adoption Model sm . In addition, CHS ... of U.S. hospitals using an electronic medical record ... for its high level of EMR usage in ...
(Date:3/23/2017)... -- Research and Markets has announced the addition of ... Industry Forecast to 2025" report to their offering. ... The Global Vehicle Anti-Theft ... 8.8% over the next decade to reach approximately $14.21 billion by ... and forecasts for all the given segments on global as well ...
(Date:3/20/2017)... Germany , March 20, 2017 At this ... Hamburg -based biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG ... is this year,s CeBIT partner country. At the largest German ... biometrics in use: fingerprint, face and iris recognition as well as DERMALOG´s ... ...
Breaking Biology News(10 mins):